Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

GlobeNewswire11-05

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481541126?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z9kcAFGwDzfNUW6QCgONwA--~B/aD0xMzgxO3c9NDA5NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/eb8b35e4636bcafaff8513420e990173","is_english":true,"pubTime":"2024-11-05 15:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481541126","market":"us","top_or_hot":-1,"title":"Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI","media":"GlobeNewswire","content":"<div>\n<p>Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nxera-pharma-antiverse-enter-collaboration-070000859.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nxera-pharma-antiverse-enter-collaboration-070000859.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies ...</p>\n\n<a href=\"https://finance.yahoo.com/news/nxera-pharma-antiverse-enter-collaboration-070000859.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UK","symbol_name":"优客工场","start_time":0,"source_url":"https://finance.yahoo.com/news/nxera-pharma-antiverse-enter-collaboration-070000859.html","article_id":"2481541126","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z9kcAFGwDzfNUW6QCgONwA--~B/aD0xMzgxO3c9NDA5NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/eb8b35e4636bcafaff8513420e990173"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481541126","pubTimestamp":1730790000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma  – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors .The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s NxWave platform, a powerful tool for GPCR target selection, validation and structural determination. The partnership aims to bring transformative therapies for multiple diseases of high unmet need. The first project will be aimed at designing antibodies with agonistic function for a challenging GPCR target.Under the terms of the multi-year agreement, Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. Nxera will retain an exclusive worldwi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"UK":"优客工场","BK4233":"房地产运营公司","BK4528":"SaaS概念","BK4007":"制药","SOLTF":"Nxera Pharma Co.,Ltd.","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4205":"房地产经营公司"},"translate_title":"Nxera Pharma和Antiverse合作利用生成式AI设计新型GPCR靶向抗体疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":1,"UK":1,"SOLTF":0.9},"content_text":"Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). \nThe collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s NxWave™ platform, a powerful tool for GPCR target selection, validation and structural determination. The partnership aims to bring transformative therapies for multiple diseases of high unmet need. The first project will be aimed at designing antibodies with agonistic function for a challenging GPCR target. \nUnder the terms of the multi-year agreement, Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. Nxera will retain an exclusive worldwide license to the antibody assets, providing full rights to develop and commercialize the candidates.\nMurat Tunaboylu, Co-founder and CEO at Antiverse, said: “Around 220 GPCRs with known disease links are undrugged, and antibodies are an essential tool in our mission to drug them. With Nxera’s expertise and support, we are confident our platform can create antibodies for these particularly challenging targets, bringing us closer to creating life-changing therapies for patients.”\nMatt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, said: “Our NxWave™ platform has proven utility in unlocking GPCRs to antibody discovery and combining Nxera’s capabilities with Antiverse’s generative AI antibody design platform enables us to explore this exciting opportunity further, with the aim of developing new biologic therapeutics for multiple diseases, where there is high unmet patient need.”\nFor Nxera, there is no material financial impact for full year 2024.\n–END–\nAbout Nxera PharmaNxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.\nIn addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.\nNxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).\nFor more information, please visit www.nxera.lifeLinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma\nAbout AntiverseAntiverse is an artificial intelligence-driven techbio company specialising in antibody design against challenging targets, including G-protein coupled receptors and ion channels. Headquartered in Cardiff, UK and with offices in Boston, USA, and Prague, Czechia, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.\nAntiverse has collaborated with multiple top global pharmaceutical companies. They are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.\nTo learn more, please visit https://antiverse.io LinkedIn: @Antiverse | X: @AntiverseHQ | YouTube: @AntiverseHQ\nEnquiries:\nNxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life\nMEDiSTRAVA – for International MediaMark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com\nAntiverse - Company Contact and Business DevelopmentMurat Tunaboylu, Co-founder and CEOMichael Mahdavi, Senior Business Development Manager+44 7718 359 109 | +1 819-319-9825 | partnerships@antiverse.io \nMedia RelationsBelle Taylor, SomXbelle@somx.health\nNxera Pharma Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481541126"}